Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by BASIL, B. Articles by BUDUR, K. Search for Related Content PubMed Citation Articles by BASIL, B. Articles by BUDUR, K. Costs, Cost Analysis Atypical Neuroleptics Conventional Neuroleptics Schizophrenia Spectrum Disorders Genetics

To the Editor:

As reported in the CATIE study, atypical antipsychotics account for more than 90% of the market share. We did a cost comparison of 1 month’s supply of the various antipsychotic drugs in the study on the online purchase site of a chain pharmacy to check for most recent prices (Table 1). The prices were checked on Sept. 28, 2005. This particular pharmacy was chosen because a majority of the patients we see fill their prescriptions there.

View this table: [in this window] [in a new window]

TABLE 1

The cost of "typical" antipsychotics (haloperidol and perphenazine) is just a fraction of that of atypical antipsychotics. Typical antipsychotics have been shown to be as effective as quetiapine, risperidone, and ziprasidone in the CATIE study. Based on the study findings and the cost comparison, we contend that the cheaper, more effective typical antipsychotics should have been considered in patients not able to afford the costlier atypical antipsychotics. But this should have been done as stated in the editorial on the basis of clinical judgment and informed patient preference (1).

References

1. Freedman R: The choice of antipsychotic drugs for schizophrenia (editorial). N Engl J Med 2005; 353:1286–1288[Free Full Text]

This article has been cited by other articles:

				R. A. Rosenheck Evaluating the cost-effectiveness of reduced tardive dyskinesia with second-generation antipsychotics The British Journal of Psychiatry, September 1, 2007; 191(3): 238 - 245. [Abstract] [Full Text] [PDF]

				R. Freedman, W. T. Carpenter JR., J. M. Davis, H. H. Goldman, C. A. Tamminga, and M. Thomas The Costs of Drugs for Schizophrenia Am J Psychiatry, December 1, 2006; 163(12): 2029 - 2031. [Full Text] [PDF]

Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by BASIL, B. Articles by BUDUR, K. Search for Related Content PubMed Citation Articles by BASIL, B. Articles by BUDUR, K. Costs, Cost Analysis Atypical Neuroleptics Conventional Neuroleptics Schizophrenia Spectrum Disorders Genetics

Get information about faster international access.

Privacy Policy

Copyright © 2006 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us